Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is N/A as of the fiscal period ended Friday, June 30, 2023.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2023 (2023-06-30): -137.40%.
RETURN ON INVESTED CAPITAL (ROIC)
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-158.54%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-279.88%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Scilex Holding Company
Market Cap
$33.58M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-158.54%
3Y Avg
-279.88%
5Y Avg
N/A
Market Cap
$33.33M
Return on Invested Capital (ROIC)
-10.09%
TTM Avg
-4.30%
3Y Avg
-1.90%
5Y Avg
0.50%
Market Cap
$33.60M
Return on Invested Capital (ROIC)
-207.97%
TTM Avg
-157.56%
3Y Avg
-117.52%
5Y Avg
-96.17%
Market Cap
$33.87M
Return on Invested Capital (ROIC)
-249.58%
TTM Avg
-1007.23%
3Y Avg
-664.86%
5Y Avg
-535.30%
Market Cap
$34.48M
Return on Invested Capital (ROIC)
-79.27%
TTM Avg
-43.87%
3Y Avg
-333.47%
5Y Avg
-212.56%
Market Cap
$34.50M
Return on Invested Capital (ROIC)
-52.61%
TTM Avg
-25.54%
3Y Avg
-42.13%
5Y Avg
-36.31%
Market Cap
$32.17M
Return on Invested Capital (ROIC)
-9.60%
TTM Avg
-4.24%
3Y Avg
-20.27%
5Y Avg
-35.08%
Market Cap
$31.44M
Return on Invested Capital (ROIC)
3.16%
TTM Avg
0.50%
3Y Avg
4.62%
5Y Avg
2.96%
Market Cap
$35.15M
Return on Invested Capital (ROIC)
-164.58%
TTM Avg
-155.30%
3Y Avg
-94.59%
5Y Avg
-73.98%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Scilex Holding Company (SCLX) | $33.58M | N/A | -158.54% | -279.88% | N/A |
| Accuray Incorporated (ARAY)vs › | $33.33M | -10.09% | -4.30% | -1.90% | 0.50% |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.60M | -207.97% | -157.56% | -117.52% | -96.17% |
| HeartBeam, Inc. (BEAT)vs › | $33.87M | -249.58% | -1007.23% | -664.86% | -535.30% |
| Elutia Inc (ELUT)vs › | $34.48M | -79.27% | -43.87% | -333.47% | -212.56% |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.50M | -52.61% | -25.54% | -42.13% | -36.31% |
| Rockwell Medical, Inc. (RMTI)vs › | $32.17M | -9.60% | -4.24% | -20.27% | -35.08% |
| Nortech Systems Incorporated (NSYS)vs › | $31.44M | 3.16% | 0.50% | 4.62% | 2.96% |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.15M | -164.58% | -155.30% | -94.59% | -73.98% |
| DocGo Inc. (DCGO)vs › | $35.57M | -89.44% | -27.62% | -11.28% | -9.71% |
ROIC
N/A
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2023-06-30 | -137.40% |
| 2023-03-31 | -216.76% |
| 2022-12-31 | -121.47% |
| 2021-09-30 | -24.52% |
| 2021-06-30 | -25.51% |
| 2021-03-31 | -26.97% |
| 2020-12-31 | -110.46% |
| 2020-09-30 | -765.88% |
| 2020-06-30 | -1089.93% |
| 2020-03-31 | -1413.98% |
